



# Prescription Drug Affordability Boards & Patient Impact

## Doctor Survey Study

Specialty doctors are worried about the impact prescription drug affordability boards will have on their practice of medicine and patients.

To gain a deeper understanding of their concerns, the Value of Care Coalition commissioned a white paper detailing the opinions of endocrinologists, rheumatologists and HIV specialists.

### KEY FINDING 1

#### Prescription drug affordability boards have not sought specialist input



- 93% did not believe there was sufficient knowledge-sharing between boards and health care providers.

### KEY FINDING 2

#### Specialty doctors aren't included in decisions that will impact health outcomes



- Less than one third said that all therapeutic options indicated for the same condition should be considered as therapeutic alternatives.



- A plurality believes the appropriateness of therapeutic alternatives depends on the individual patient's clinical needs and preferences.



- 93% are concerned prescription drug affordability boards unaffiliated with a state medical board will make decisions that may hinder patient access to needed medications.

### KEY FINDING 3

#### Prescription drug affordability boards' decisions will impede patient care



- 100% are concerned that decisions made by prescription drug affordability boards will lead to additional administrative burdens for staff that cut into patient care time.



- 96% were somewhat or very concerned upper payment limits may lead to non-medical switching, which forces patients to take a medicine not preferred by their doctor.



**The results are clear: Specialty doctors know they should be the ones making decisions about their patients' treatment – not prescription drug affordability boards.**